{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,25]],"date-time":"2026-04-25T10:57:13Z","timestamp":1777114633642,"version":"3.51.4"},"reference-count":22,"publisher":"MDPI AG","issue":"12","license":[{"start":{"date-parts":[[2025,12,3]],"date-time":"2025-12-03T00:00:00Z","timestamp":1764720000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Current Oncology"],"abstract":"<jats:p>Primary urethral cancer is an extremely rare malignancy, accounting for less than 1% of all cancers. Due to its rarity, evidence-based treatment recommendations are lacking. We report the case of a 44-year-old woman with metastatic squamous cell urethral carcinoma and paraneoplastic Sweet syndrome. The tumor was p16-positive with strong PD-L1 expression (CPS &gt; 50%). Following surgery and adjuvant chemoradiotherapy, the patient developed hepatic and lymph node metastases. Pembrolizumab was initiated as first-line systemic therapy because of prior hematologic toxicity with cisplatin. After four cycles, complete radiologic remission of metastases and full resolution of the Sweet syndrome were achieved. This case highlights the potential benefit of immune checkpoint inhibitors in metastatic urethral SCC, particularly in p16-positive and PD-L1-high tumors, suggesting an inflamed and immunogenic microenvironment. To our knowledge, this is the first reported case of paraneoplastic Sweet syndrome successfully treated with pembrolizumab. These findings underscore the need for further investigation of immunotherapy in this rare and challenging malignancy.<\/jats:p>","DOI":"10.3390\/curroncol32120683","type":"journal-article","created":{"date-parts":[[2025,12,5]],"date-time":"2025-12-05T17:35:17Z","timestamp":1764956117000},"page":"683","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["A Rare Case of Metastatic Urethral Squamous Cell Carcinoma Presenting with Paraneoplastic Sweet Syndrome and Treated with Pembrolizumab"],"prefix":"10.3390","volume":"32","author":[{"ORCID":"https:\/\/orcid.org\/0009-0000-1447-5195","authenticated-orcid":false,"given":"Dan-Thanh Christine","family":"Nguyen","sequence":"first","affiliation":[{"name":"Department of Hematology-Oncology, Centre Hospitalier de l\u2019Universit\u00e9 de Montr\u00e9al, Montr\u00e9al, QC H2X 1R6, Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0009-0004-2096-8307","authenticated-orcid":false,"given":"Zineb","family":"Hamilou","sequence":"additional","affiliation":[{"name":"Department of Hematology-Oncology, Centre Hospitalier de l\u2019Universit\u00e9 de Montr\u00e9al, Montr\u00e9al, QC H2X 1R6, Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Evelyne","family":"Bonnardeaux","sequence":"additional","affiliation":[{"name":"Department of Dermatology, Centre Hospitalier de l\u2019Universit\u00e9 de Montr\u00e9al, Montr\u00e9al, QC H2X 1R6, Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2698-4362","authenticated-orcid":false,"given":"Normand","family":"Blais","sequence":"additional","affiliation":[{"name":"Department of Hematology-Oncology, Centre Hospitalier de l\u2019Universit\u00e9 de Montr\u00e9al, Montr\u00e9al, QC H2X 1R6, Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9890-650X","authenticated-orcid":false,"given":"Manon","family":"de Vries-Brilland","sequence":"additional","affiliation":[{"name":"Department of Hematology-Oncology, Centre Hospitalier de l\u2019Universit\u00e9 de Montr\u00e9al, Montr\u00e9al, QC H2X 1R6, Canada"},{"name":"Department of Medical Oncology, Integrated Centers of Oncology (ICO) Paul Papin, 49055 Angers, France"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1968","published-online":{"date-parts":[[2025,12,3]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1016\/j.ajur.2022.04.005","article-title":"A brief review on the diagnostic and therapeutic principles of primary urethral cancer","volume":"9","author":"Su","year":"2022","journal-title":"Asian J. Urol."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"170","DOI":"10.4103\/UA.UA_136_17","article-title":"Primary urethral carcinoma: A Surveillance, Epidemiology, and End Results data analysis identifying predictors of cancer-specific survival","volume":"10","author":"Aleksic","year":"2018","journal-title":"Urol. Ann."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1111\/bju.16334","article-title":"Urethral cancer: A comprehensive review endorsed by the Global Society of Rare Genitourinary Tumours","volume":"134","author":"Summers","year":"2024","journal-title":"BJU Int."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1186\/s12943-024-02095-8","article-title":"Programmed death receptor (PD-)1\/PD-ligand (L)1 in urological cancers: The \u201call-around warrior\u201d in immunotherapy","volume":"23","author":"Liu","year":"2024","journal-title":"Mol. Cancer"},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1200\/OP.22.00802","article-title":"Immunotherapy and Biomarker Testing in Recurrent and Metastatic Head and Neck Cancers: ASCO Guideline Q and A","volume":"19","author":"Yilmaz","year":"2023","journal-title":"JCO Oncol. Pract."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"1856","DOI":"10.1056\/NEJMoa2112435","article-title":"Pembrolizumab for Persistent, Recurrent, or Metastatic Cervical Cancer","volume":"385","author":"Colombo","year":"2021","journal-title":"N. Engl. J. Med."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"2040","DOI":"10.1056\/NEJMoa1810865","article-title":"Pembrolizumab plus Chemotherapy for Squamous Non-Small-Cell Lung Cancer","volume":"379","author":"Luft","year":"2018","journal-title":"N. Engl. J. Med."},{"key":"ref_8","doi-asserted-by":"crossref","unstructured":"Clancy, K., Hamill, C.S., O\u2019Neill, W.Q., Vu, B., Thuener, J., Gui, S., Li, S., Fowler, N., Rezaee, R., and Lavertu, P. (2021). Impact of p16 Status and Anatomical Site in Anti-PD-1 Immunotherapy-Treated Recurrent\/Metastatic Head and Neck Squamous Cell Carcinoma Patients. Cancers, 13.","DOI":"10.3390\/cancers13194861"},{"key":"ref_9","first-page":"100532","article-title":"Predictive Value of Combined Positive Score and Tumor Proportion Score for Immunotherapy Response in Advanced NSCLC","volume":"4","author":"Ulas","year":"2023","journal-title":"JTO Clin. Res. Rep."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"1516","DOI":"10.3892\/ijo.2013.1874","article-title":"Insight into Sweet\u2019s syndrome and associated-malignancy: A review of the current literature","volume":"42","author":"Raza","year":"2013","journal-title":"Int. J. Oncol."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"1754","DOI":"10.1093\/annonc\/mdv230","article-title":"Impact of perioperative chemotherapy on survival in patients with advanced primary urethral cancer: Results of the international collaboration on primary urethral carcinoma","volume":"26","author":"Gakis","year":"2015","journal-title":"Ann. Oncol."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1016\/j.ucl.2010.04.010","article-title":"Chemotherapy for penile and urethral carcinoma","volume":"37","author":"Trabulsi","year":"2010","journal-title":"Urol. Clin. North Am."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"905","DOI":"10.1097\/COC.0000000000000391","article-title":"Treatment and Outcomes of Primary Urethra Cancer","volume":"41","author":"Eng","year":"2018","journal-title":"Am. J. Clin. Oncol."},{"key":"ref_14","doi-asserted-by":"crossref","unstructured":"Wenzel, M., Deuker, M., Nocera, L., Ruvolo, C.C., Tian, Z., Shariat, S.F., Saad, F., Briganti, A., Becker, A., and Kluth, L.A. (2020). Comparison Between Urothelial and Non-Urothelial Urethral Cancer. Front. Oncol., 10.","DOI":"10.3389\/fonc.2020.629692"},{"key":"ref_15","doi-asserted-by":"crossref","unstructured":"Wang, J., Sun, H., Zeng, Q., Guo, X.J., Wang, H., Liu, H.H., and Dong, Z.-Y. (2019). HPV-positive status associated with inflamed immune microenvironment and improved response to anti-PD-1 therapy in head and neck squamous cell carcinoma. Sci. Rep., 9.","DOI":"10.1038\/s41598-019-49771-0"},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"3000605221132418","DOI":"10.1177\/03000605221132418","article-title":"Chemotherapy combined with immunotherapy in primary female urethral squamous cell carcinoma: A case report","volume":"50","author":"Bai","year":"2022","journal-title":"J. Int. Med. Res."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"2723","DOI":"10.1002\/1097-0142(19931101)72:9<2723::AID-CNCR2820720933>3.0.CO;2-F","article-title":"Sweet syndrome in patients with solid tumors","volume":"72","author":"Cohen","year":"1993","journal-title":"Cancer"},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1007\/s40257-022-00673-4","article-title":"New Practical Aspects of Sweet Syndrome","volume":"23","author":"Joshi","year":"2022","journal-title":"Am. J. Clin. Dermatol."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"1499","DOI":"10.1007\/s00277-022-04850-7","article-title":"Characteristics of Sweet syndrome in patients with or without malignancy","volume":"101","author":"Jung","year":"2022","journal-title":"Ann. Hematol."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"E7","DOI":"10.12788\/cutis.0798","article-title":"Dupilumab-Associated Sweet Syndrome","volume":"111","author":"Fernandez","year":"2023","journal-title":"Cutis"},{"key":"ref_21","first-page":"e62027","article-title":"A Rare Case of Drug-Induced Sweet Syndrome After Pembrolizumab Therapy","volume":"16","author":"Muralidharan","year":"2024","journal-title":"Cureus"},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1016\/j.currproblcancer.2016.12.001","article-title":"Cutaneous adverse effects of the immune checkpoint inhibitors","volume":"41","author":"Collins","year":"2017","journal-title":"Curr. Probl. Cancer"}],"container-title":["Current Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1718-7729\/32\/12\/683\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,5]],"date-time":"2025-12-05T18:20:53Z","timestamp":1764958853000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1718-7729\/32\/12\/683"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12,3]]},"references-count":22,"journal-issue":{"issue":"12","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["curroncol32120683"],"URL":"https:\/\/doi.org\/10.3390\/curroncol32120683","relation":{},"ISSN":["1718-7729"],"issn-type":[{"value":"1718-7729","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,12,3]]}}}